Arrowhead Pharmaceuticals
ARWR
61.48
-0.06
-0.10%
Arrowhead Pharmaceuticals
US · ARWR
#1569 by market cap
Listed 1970
61.48
-0.06
-0.10%
Live - 5344 symbols - heartbeat 185s ago
· 2026-10-08 06:51
Pre-market
60.60
-1.43%
After-hours
61.48
0.00%
Overnight
61.48
0.00%
- Market cap
- 8.68B
- P/E (TTM)i
- -26.96
- P/Bi
- 18.65
- EPSi
- -0.01
- Div yieldi
- 0.00%
- 52W posi
- 44%
Reader sentiment
Are you bullish or bearish on ARWR?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 12 analysts
Buy
Avg price target
109.11 +77.5%
Price target rangecurrent 61.48
Low74.00
Avg109.11
High126.00
Buy 92%
Hold 8%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-24 | Goldman Sachs | -- | HOLD | 74.00 |
| 2026-09-21 | H.C. Wainwright | -- | BUY | 120.00 |
| 2026-09-16 | Citi | -- | BUY | -- |
| 2026-09-15 | J.P. Morgan | -- | BUY | -- |
| 2026-09-09 | Citi | -- | BUY | 108.00 |
| 2026-09-08 | Citi | -- | BUY | 108.00 |
| 2026-09-01 | H.C. Wainwright | -- | BUY | 120.00 |
| 2026-08-31 | Morgan Stanley | -- | BUY | 120.00 |
| 2026-08-31 | Stifel | -- | BUY | 104.00 |
| 2026-08-31 | J.P. Morgan | -- | BUY | -- |
| 2026-08-30 | TD Cowen | -- | BUY | -- |
| 2026-08-30 | RBC Capital | -- | BUY | 100.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 120.00 |
| 2026-08-06 | Morgan Stanley | -- | BUY | 120.00 |
| 2026-08-06 | H.C. Wainwright | -- | BUY | 120.00 |
| 2026-08-06 | J.P. Morgan | -- | BUY | 100.00 |
| 2026-08-05 | Piper Sandler | -- | BUY | 126.00 |
| 2026-08-05 | Morgan Stanley | -- | BUY | 120.00 |
| 2026-08-05 | Stifel | -- | BUY | 104.00 |
| 2026-08-05 | B. Riley Securities | -- | BUY | 123.00 |
| 2026-08-05 | RBC Capital | -- | BUY | 100.00 |
| 2026-08-04 | TD Cowen | -- | BUY | 89.59 |
| 2026-08-04 | Chardan Capital | -- | BUY | 115.00 |
| 2026-08-04 | BofA Securities | -- | BUY | 100.00 |
| 2026-07-30 | B. Riley Securities | -- | BUY | 123.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Morgan Stanley moved from Hold to Buy on 2026-04-21.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-04-21 | Morgan Stanley | HOLD → BUY | 100.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-08-04 | After close | ±8.92% | -2.99% (in line) |
| 2026/Q2 | 2026-05-07 | After close | ±7.25% | -6.75% (in line) |
| 2026/Q1 | 2026-02-05 | After close | ±11.93% | -0.19% (in line) |
| 2025/Q4 | 2025-11-25 | After close | ±13.52% | +23.34% (beat) |
| 2025/Q3 | 2025-08-07 | After close | ±13.30% | +2.24% (in line) |
| 2025/Q2 | 2025-05-12 | After close | ±11.99% | +9.38% (in line) |
| 2025/Q1 | 2025-02-10 | After close | ±10.83% | -5.17% (in line) |
| 2024/Q4 | 2024-11-26 | After close | ±15.02% | +24.23% (beat) |
| 2024/Q3 | 2024-08-08 | After close | ±12.75% | -9.44% (in line) |
| 2024/Q2 | 2024-05-09 | After close | ±10.35% | -10.68% (beat) |
| 2023/Q4 | 2023-11-29 | After close | ±12.00% | -26.85% (beat) |
| 2023/Q3 | 2023-08-07 | After close | ±8.93% | -10.78% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 06:51:28 · For reference only, not investment advice and not tailored to your situation.